Clinical Trial Update: A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing sequential satraplatin and erlotinib versus erlotinib alone in unresectable stage 3/4 non-small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• satraplatin (satraplatin)

Snippet

Sponsor: Agennix | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED